Coherus Oncology Inc (CHRS) financials
Coherus Oncology revenue and earnings by year
Coherus Oncology's revenue was $42.2 million in the fiscal year to December 31, 2025, up 59.8% from the year before. Net income was $168 million, 398.4% of revenue. Since the fiscal year to December 31, 2016, revenue has shrunk 15.4% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 9 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 42 | 26 | 257 | 211 | 327 | 476 | 356 | 2 | 190 |
| Revenue growth | 59.8% | -89.7% | 21.9% | -35.4% | -31.4% | 33.6% | 22783.7% | -99.2% | — |
| Gross profit | 28 | 18 | 98 | 141 | 269 | 438 | 339 | — | — |
| Gross margin | 67.2% | 66.9% | 38.2% | 66.8% | 82.4% | 92.1% | 95.2% | — | — |
| Operating income | -181 | -200 | -203 | -257 | -264 | 156 | 108 | -232 | -116 |
| Operating margin | -429.5% | -756.6% | -79.0% | -121.7% | -80.8% | 32.9% | 30.3% | -14918.8% | -61.0% |
| Net income | 168 | 29 | -238 | -292 | -287 | 132 | 90 | -238 | -127 |
| Net margin | 398.4% | 108.0% | -92.5% | -138.2% | -87.9% | 27.8% | 25.2% | -15306.6% | -67.0% |
| Diluted EPS | $1.43 | $0.27 | -$2.60 | -$3.76 | -$3.81 | $1.62 | $1.19 | -$4.51 | -$3.43 |
| Free cash flow | -139 | -20 | -175 | -241 | -39 | 147 | 27 | -205 | -259 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open CHRS in Markets.
How Coherus Oncology makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Toripalimab | $13.6M | 95.1% |
| Product & Service Other | $694K | 4.9% |
See also: CHRS valuation and P/E history · CHRS returns
No forecast, no recommendation. This page describes Coherus Oncology Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.